Jul 16, 2025 | Legal Compliance, State-Specific Regulations
Florida’s new noncompete legislation—the Contracts Honoring Opportunity, Investment, Confidentiality, and Economic Growth Act, also known as the CHOICE Act—took effect on July 1, 2025. Designed to support employers, this law expands the enforceability of restrictive...
Jul 16, 2025 | Legal Compliance, News, State-Specific Regulations
Colorado’s House Bill 25-1024 (HB25-1024), signed into law on April 7, 2025, adds critical obligations for medical professionals who delegate medical-aesthetic procedures to unlicensed staff. If you’re a Colorado physician or advanced practice registered nurse...
Jul 15, 2025 | Legal Compliance, News
Semaglutide, the active ingredient in Ozempic and Wegovy, is set to lose patent protection in China on March 20, 2026. This is years ahead of its expiration in the United States, Europe and Japan. As that date approaches, Chinese pharmaceutical companies (as well as...
Jul 9, 2025 | Legal Compliance, Starting a Business, State-Specific Regulations
With IV hydration therapy clinics rapidly gaining popularity across the country, Wisconsin regulators are stepping in to clarify who can legally assess, prescribe, mix, and administer these treatments. In a new Joint Advisory Opinion issued June 25, 2025, six...
Jul 9, 2025 | Legal Compliance, Starting a Business, State-Specific Regulations
Good Faith Exams Are Still Required IV hydration therapy is medical care. That means every IV treatment must be: Based on a valid, individualized order from a Licensed Provider (LP) with prescriptive authority (such as a physician, PA, or NP); and Issued after a...
Jun 18, 2025 | Legal Compliance, News
Novo Nordisk, the pharmaceutical company behind Ozempic and Wegovy, is starting to lose its wave of lawsuits against compounders and related businesses offering semaglutide copycats. But here’s the reality that isn’t making headlines: even when Novo loses, the process...
